SemBioSys announces second quarter 2008 financial and operation... (se Phase I/II clinical trial of s...)

SemBioSys announces second quarter 2008 financial and operational results

Date:8/5/2008

se Phase I/II clinical

trial of safflower-produced insulin in the United Kingdom in the

fourth quarter of 2008.

- Continuation of business development activities toward an insulin

partnership.

In 2007, SemBioSys successfully achieved commercial levels of both Apo AI and Apo AI(Milano) accumulation in safflower. With positive results demonstrating safflower-produced Apo AI(Milano) increased cholesterol mobilization in animals earlier this year, SemBioSys is continuing testing in animals to establish that safflower-produced Apo AI(Milano) is equivalent to microbial-produced Apo AI(Milano) with respect to plaque-remodeling and plaque regression. The upcoming milestone events include:

- Completion of in vivo efficacy studies of plaque remodeling with

safflower-produced Apo AI(Milano) followed by studies of plaque

regression using a mouse model.

- Continuation of the formal partnering process for safflower-produced

Apo AI(Milano). The Company has already initiated confidential

discussions with several potential large pharmaceutical partners.

In addition to its pharmaceutical milestones, SemBioSys also expects to collect milestone payments from Arcadia Biosciences, Inc., upon their successful commercial scale-up and market launch of High GLA Safflower Oil in late 2008 or early 2009.

Meanwhile, Botaneco is also advancing the development of its personal care ingredient products with the expansion of the commercial distribution of Hydresia(TM) and Hydresia(TM) G2. With the completion of the recent funding transaction with Avrio, along with the previously committed $2.4 million from AVAC Ltd., SemBioSys expects Botaneco to be self-financing moving forward.

"The progress we have made with our two lead pharmaceutical programs, insulin and Apo AI(Milano), over the past few months has transformed SemBioSys. We are now poised to have insulin enter the cli
'/>"/>

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related biology technology :

1. SemBioSys submits IND for safflower-produced insulin to U.S. FDA
2. SemBioSys Demonstrates Functionality of its Safflower Produced Apo AI(Milano)
3. SemBioSys to present at the Needham & Company Biotechnology and Medical Technology Conference
4. SemBioSys provides update on shrimp feed additive, Immunosphere(TM)
5. SemBioSys announces first quarter 2008 financial and operational results
6. SemBioSys receives milestone payments from AVAC Ltd.
7. SemBioSys initiates toxicology study for safflower-produced insulin
8. SemBioSys announces 2007 financial and operational results
9. SemBioSys GLA Partner Enters Strategic Alliance for the Sales and Marketing of GLA-Rich Safflower Oil
10. SemBioSys awarded key patent for the production of oleosome emulsions by the European Patent Office
11. SemBioSys to present at the 10th Annual BIO CEO & Investor Conference

Post Your Comments:

SemBioSys announces second quarter 2008 financial and operation...(se Phase I/II clinical trial of s...)